Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis Treated with Canakinumab Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Antirheumatic Agents
  • Arthritis, Juvenile
  • Macrophage Activation Syndrome

abstract

  • Canakinumab does not have a significant effect on MAS risk or its clinical features in patients with systemic JIA. Infections are the most common trigger, and MAS occurs even in patients whose systemic JIA is well controlled with this treatment.

publication date

  • January 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1002/art.39407

PubMed ID

  • 26314396

Additional Document Info

start page

  • 218

end page

  • 28

volume

  • 68

number

  • 1